INS and metabolic syndrome: Specifically, a few studies showed that drugs acting on RAA system and, in particular, ARBs could improve metabolic status in patients with metabolic syndrome [32], decreasing visceral fat accumulation [33] and improving insulin sensitivity and lipid profile [34], whereas visceral adiposity increases the risk of developing adverse metabolic effects upon treatment with β-blockers or thiazide diuretics [35].